Athlete's Foot (Tinea Pedis)

Clinical Snapshot

Tinea pedis ("athlete's foot") is a dermatophyte infection of the skin of the foot, most often caused by Trichophyton rubrum and Trichophyton interdigitale, and is the most common dermatophyte infection encountered in practice.^[1] It presents in several distinct patterns — interdigital, moccasin (hyperkeratotic), vesiculobullous, and the rare ulcerative type — each with a different appearance, a different natural history, and in some cases a different treatment approach, so recognizing which subtype is in front of you matters more than reflexively reaching for "the athlete's foot cream."^[1] Most uncomplicated tinea pedis is genuinely a self-care condition: a topical antifungal matched to the subtype and continued for the full course — even after itching resolves — cures the great majority of cases without prescription therapy being required.^[2] The pharmacist's core value here is threefold: confirming this really is tinea pedis and not one of its many mimics, matching the right topical agent and duration to the presentation, and recognizing the minority of patients — diabetes, peripheral vascular disease, immunosuppression, or spreading erythema — who need to be moved out of self-care and into medical assessment.

Recognize the Condition

The 4 clinical subtypes of tinea pedis

Interdigital (most common)

Erythema, scaling, peeling, and maceration in the web spaces, classically starting between the 4th and 5th toes. The skin can look white and soggy from retained moisture. Pruritus is the dominant symptom; fissuring at the base of the web space causes pain and burning and is a common portal for secondary bacterial infection.^[1]

Interdigital tinea pedis between the 3rd and 4th toes showing scaling and maceration of the web-space skin

Interdigital tinea pedis of the 3rd-4th web space, showing scaling and maceration of the moist web-space skin — the most common tinea pedis presentation. (Tang21237, CC BY-SA 4.0, Wikimedia Commons)

Moccasin (chronic hyperkeratotic)

Diffuse, chronic scaling with variable underlying erythema across the sole, heel, and the medial and lateral borders of the foot, in a distribution resembling a moccasin shoe, often with a fine "collarette" of scale at the edge. Usually caused by T. rubrum, typically minimally symptomatic, and notably resistant to short courses of topical therapy — this is the subtype most likely to need an extended topical course or oral therapy.^[1]

Moccasin-type tinea pedis showing diffuse scaling and erythema across both soles

Moccasin (chronic hyperkeratotic) tinea pedis, with diffuse scaling and erythema across the sole in a distribution resembling a moccasin shoe. (Dr. Gannavarapu Narasimhamurthy, CC0 public domain, Wikimedia Commons)

Vesiculobullous (inflammatory)

Intensely pruritic, sometimes painful, 1-3 mm vesicles or bullae on an erythematous base, typically on the instep or medial foot. Vesicles rupture to leave a raw, weeping surface. A remote, symmetric vesicular eruption on the hands (a dermatophytid or "id" reaction) accompanies a meaningful minority of cases and resolves on its own once the foot infection is treated — it is not a separate infection and does not need its own antifungal therapy.^[1]

Ulcerative (uncommon)

Rapidly spreading interdigital erosions and ulcers, more aggressive than the vesiculobullous pattern and frequently complicated by secondary bacterial infection (cellulitis, lymphangitis). Seen disproportionately in patients with diabetes, peripheral vascular disease, or immunodeficiency — this presentation should prompt the red-flag assessment below rather than routine self-care.^[1]

A fifth pattern, occult tinea pedis, shows no visible lesions at all despite active infection and is most often identified incidentally or in athletes — a reminder that a normal-looking foot does not exclude dermatophyte carriage in a patient with recurrent reinfection, or unexplained spread to the nails or groin.^[1]

Risk Factors

Occlusive, non-breathable footwear and prolonged shoe-wearing without rotation between pairs.
Communal bathing facilities, public pool decks, and shared gym or locker-room showers.
Hyperhidrosis (excess sweating), particularly plantar hyperhidrosis.
Male sex — roughly 3 times the risk of females — and age 16-45, though any age can be affected.^[1]
Diabetes mellitus, peripheral vascular disease, and immunodeficiency.
Concurrent atopic dermatitis or psoriasis.
Obesity.
Occupational or living exposure — athletes, military personnel, manual laborers, and long-term care or shelter residents.^[1]
A personal history of tinea pedis or onychomycosis, or a household contact with either.

Red Flags & Refer

Most tinea pedis is appropriate for self-care, but escalate to medical assessment — and treat as possible cellulitis rather than simple tinea — for any of the following:

Spreading erythema, warmth, swelling, or pain extending beyond the original lesion, red streaking up the leg (lymphangitis), or fever/chills — these suggest secondary bacterial cellulitis rather than uncomplicated fungal infection and need urgent assessment, not an antifungal alone.^[3]
The ulcerative subtype (rapidly spreading interdigital erosions/ulcers) — this pattern is frequently complicated by bacterial superinfection and disproportionately affects patients with diabetes, peripheral vascular disease, or immunodeficiency.^[1]
Diabetes or peripheral vascular disease with any active tinea pedis — fungal and secondary bacterial foot infections carry up to a 3-fold higher risk of complications such as cellulitis, and up to a 5-fold higher risk of gangrene, in patients with diabetes; treat these patients more actively and with a lower threshold for referral and prescription oral therapy rather than a standard self-care trial.^[3]
Immunocompromise (including poorly controlled HIV, transplant recipients, or active chemotherapy) — presentation can be extensive or atypical, and self-care is not appropriate as the sole management.
Extensive disease covering a large surface area, or disease that has already spread to the nails (onychomycosis), the groin (tinea cruris), or the hands (tinea manuum) — a topical trial limited to the foot will not address the reservoir driving reinfection.
No improvement, or worsening, after a full and adherent course of an appropriately chosen topical antifungal — this needs diagnostic reassessment, not simply switching to another topical agent empirically.
Diagnostic uncertainty — a presentation that does not fit typical tinea pedis (symmetric, bilateral, sharply demarcated plaques favor psoriasis or contact dermatitis over tinea) warrants confirmation before treating.

Assessment & Diagnosis

History

Characterize the distribution (interdigital, sole/heel/moccasin, vesicular, or ulcerative) and ask specifically about pruritus, burning, pain, and how long the presentation has been evolving.
Ask about footwear habits, communal shower/pool exposure, hyperhidrosis, and whether household contacts have similar symptoms.
Screen for diabetes, peripheral vascular disease, and immunosuppression — these change both the urgency of assessment and the treatment plan.
Ask about prior self-treatment: which product, how it was applied, and for how long — premature discontinuation once itching resolves is the most common reason an apparent "treatment failure" is really an incomplete course.^[1]

Examination

Confirm the distribution matches one of the 4 subtypes above, and specifically check for fissuring, maceration, or frank drainage suggesting secondary bacterial infection, and for spreading erythema, warmth, or lymphangitic streaking suggesting cellulitis.

Differential diagnosis

Condition	Features that point away from tinea pedis
Irritant or allergic contact dermatitis (footwear dyes, adhesives, rubber accelerators)	Distribution often matches the shoe/sock contact pattern rather than the classic web-space or moccasin pattern; frequently symmetric and bilateral.
Atopic or dyshidrotic (pompholyx) eczema	Symmetric, bilateral involvement; personal or family history of atopy; deep-seated palmar/plantar vesicles without the web-space predilection of interdigital tinea.
Palmoplantar psoriasis	Well-demarcated, symmetric, often thicker plaques with a silvery scale; look for psoriatic nail changes or plaques elsewhere on the body.
Pitted keratolysis	Punched-out pits on the weight-bearing sole with a distinctive malodor — a bacterial, not fungal, process.
Erythrasma	Interdigital, but caused by Corynebacterium minutissimum; coral-red fluorescence under Wood's lamp helps distinguish it (tinea pedis does not fluoresce).
Candidal intertrigo	Beefy-red erythema with satellite pustules; more maceration/occlusion; needs an anti-yeast rather than a dermatophyte-only agent.
Bacterial infection (impetigo, early cellulitis)	Honey-crusted lesions, or spreading warm erythema with pain/fever, rather than the chronic scaling typical of tinea.
Scabies	Intense nocturnal pruritus, burrows, and involvement of finger web spaces, wrists, and genitals in addition to the feet.

Most classic interdigital or moccasin-pattern disease can be diagnosed clinically without testing. Confirm the diagnosis with a potassium hydroxide (KOH) preparation of a skin scraping from the active, scaling border (or a fungal culture, or an in-office dermatophyte test strip where available) whenever the presentation is atypical, before starting oral therapy, or when an initial topical course has failed — this avoids weeks of ineffective self-treatment for what may actually be psoriasis, contact dermatitis, or a bacterial process.^[1]

Treatment Targets

Achieve mycological cure of the dermatophyte infection, not just symptom relief.
Resolve pruritus, fissuring, and discomfort.
Prevent secondary bacterial infection and, in at-risk patients, cellulitis.
Prevent spread to the nails, groin, hands, or household contacts.
Reduce recurrence through footwear and foot-hygiene measures, since tinea pedis is one of the more frequently recurrent dermatophyte infections.

Choose Initial Treatment

Direct treatment rule

Step 1 — most uncomplicated tinea pedis is topical, first-line self-care

Interdigital tinea pedis, 1st line topical terbinafine 1% cream applied twice daily for 1 week — a 1-week course of terbinafine achieves comparable or superior cure rates to 4 weeks of an azole, with markedly better adherence given the shorter course.^[2]^[4]

Azole alternative clotrimazole 1% or miconazole 2% cream applied twice daily for 4 weeks — effective, inexpensive, and widely available without a prescription, but needs a longer, harder-to-complete course and achieves a somewhat lower cure rate than terbinafine in head-to-head trials.^[2]

Tolnaftate 1% applied twice daily for 2-4 weeks is another nonprescription option, but it is fungistatic rather than fungicidal and has no activity against Candida — avoid it when the presentation could represent candidal intertrigo rather than a pure dermatophyte infection.

Step 2 — the moccasin (hyperkeratotic) pattern needs a longer course

Use the same topical agents but plan for a longer course — typically 4 weeks at minimum, sometimes longer — since the thickened stratum corneum limits drug penetration and this subtype is the most treatment-resistant.^[1] A salicylic acid keratolytic applied concurrently can improve penetration and speed clinical response by softening hyperkeratotic scale.

Step 3 — reserve oral (systemic) therapy for the right patients

Move to oral therapy for extensive or widespread disease, chronic moccasin-type disease that has not responded to an adequate topical course, immunocompromised patients, or when tinea pedis coexists with onychomycosis — the infected nail acts as an ongoing fungal reservoir that will keep reseeding the skin.^[1]

Oral terbinafine, 1st line oral agent 250 mg once daily for 2 weeks — effective, has fewer clinically significant drug interactions than the oral azoles, and outperforms both itraconazole and griseofulvin in comparative evidence.^[1]

Oral itraconazole 200 mg twice daily for 1 week (pulse dosing) is an effective alternative — screen carefully for CYP3A4 interactions before prescribing, since itraconazole is a potent CYP3A4 inhibitor.^[1]

Oral fluconazole 150 mg once weekly for 2-6 weeks is a further alternative when terbinafine and itraconazole are not suitable.^[1]

Avoid oral griseofulvin and oral ketoconazole as routine choices — griseofulvin has poor bioavailability, needs a longer course, and carries more adverse effects (photosensitivity, GI upset, hepatic effects) than terbinafine, and oral ketoconazole has been largely abandoned given its hepatotoxicity and adrenal/neurologic risk relative to the alternatives above.^[1]

Step 4 — treat secondary bacterial infection if present

A macerated, malodorous, or frankly infected interdigital space (the "dermatophytosis complex") needs treatment directed at the bacterial component as well — an antifungal with combined antibacterial activity (e.g., ciclopirox) or a short course of an oral antibiotic for true cellulitis, in addition to antifungal therapy for the underlying tinea.^[1]

Non-Pharmacologic Treatment

Dry the feet thoroughly, especially between the toes, after every bath, shower, or swim — moisture is the single biggest driver of both initial infection and recurrence.
Wear moisture-wicking or cotton socks and change them at least daily, more often if the feet sweat heavily.
Choose breathable, non-occlusive footwear; alternate between at least 2 pairs of shoes so each can fully dry out between wears.
Wear sandals or shower shoes in communal showers, pool decks, and gym locker rooms rather than going barefoot.
Apply a desiccating or antifungal powder (e.g., miconazole or tolnaftate powder) to the feet and inside footwear to control moisture and reduce recurrence, particularly with hyperhidrosis.^[1]
Disinfect or discard heavily infected footwear — hot laundering of socks, and UV-C or ozone shoe sanitizing where available, reduce the fungal reservoir that drives reinfection.^[1]
Do not share towels, socks, shoes, or nail-care tools with household members.
Treat any concurrent onychomycosis or tinea at another body site (groin, hands) at the same time — an untreated nail or skin reservoir is one of the most common causes of "recurrent" tinea pedis.
Manage plantar hyperhidrosis directly (for example, an antiperspirant containing aluminum chloride) if it is a recurring contributor.

Set the expectation explicitly at the first visit: continue the full course even after itching and visible scaling resolve. Stopping as soon as symptoms improve — before the mycological cure point — is the single most common, and most avoidable, cause of apparent treatment failure and early recurrence.^[1]

Pharmacologic Treatment Options

Drug / intervention	Role	Dose / use	Important adverse effects	Teaching points
Terbinafine 1% cream (topical) Preferred	1st-line topical agent, interdigital tinea pedis	Apply BID for 1 week (moccasin-type: BID for up to 4 weeks or longer)	Local irritation, burning, stinging	Shortest effective course of any topical option; complete the full course even after itching resolves.
Clotrimazole 1% cream Alternative	OTC azole alternative	Apply BID for 4 weeks	Local irritation, burning	Effective and inexpensive but needs a longer course than terbinafine; adherence over 4 weeks is the main limiting factor.
Miconazole 2% cream Alternative	OTC azole alternative	Apply BID for 4 weeks	Local irritation, burning	Comparable efficacy and dosing rationale to clotrimazole.
Tolnaftate 1% cream/solution/powder Alternative	OTC option; also used as a preventive powder	Apply BID for 2-4 weeks (treatment); once daily to feet/footwear for prevention	Local irritation (uncommon)	Fungistatic, not fungicidal, and has no activity against Candida — avoid if a yeast component is suspected.
Ciclopirox 0.77% cream Special situation	Dermatophytosis complex (mixed fungal/secondary bacterial colonization or odour)	Apply BID for up to 4 weeks	Local irritation	Combined antifungal, anticandidal, and antibacterial activity — useful when secondary bacterial colonization is present alongside the fungal infection.
Salicylic acid keratolytic Special situation	Adjunct for moccasin (hyperkeratotic) tinea pedis	Apply per product directions concurrently with the antifungal	Local irritation	Softens hyperkeratotic scale to improve antifungal penetration; not an antifungal itself.
Terbinafine (oral) Preferred	1st-line oral agent for extensive, refractory, or moccasin-type disease	250 mg PO once daily for 2 weeks	GI upset, headache, transient taste/smell disturbance; rare hepatotoxicity	Fewer clinically significant drug interactions than the oral azoles; obtain baseline liver function tests if other hepatotoxicity risk factors are present.
Itraconazole (oral, pulse) Alternative	Alternative oral agent	200 mg PO BID for 1 week	GI upset, headache; rare hepatotoxicity	Potent CYP3A4 inhibitor — screen the full medication list before prescribing.
Fluconazole (oral) Alternative	Further alternative when terbinafine/itraconazole are unsuitable	150 mg PO once weekly for 2-6 weeks	GI upset, headache	Lower comparative efficacy than terbinafine or itraconazole; reserve for intolerance/contraindication to the preferred oral agents.

Special Populations

Pregnancy

Topical antifungal therapy is preferred in pregnancy given minimal systemic absorption — topical terbinafine, clotrimazole, and miconazole are all reasonable choices.

Avoid oral therapy where possible: oral fluconazole and itraconazole carry teratogenicity signals at the doses used for dermatophyte infections, and griseofulvin is specifically contraindicated in pregnancy. If oral therapy is genuinely unavoidable, this decision should be made by the prescriber weighing the specific clinical picture, not defaulted to.

Breastfeeding

Topical antifungals are compatible with breastfeeding given minimal systemic absorption. Data on the oral agents in lactation are more limited; apply the same benefit/risk judgment as in pregnancy if oral therapy is being considered.

Pediatrics

Topical therapy is preferred in children — no dose adjustment or laboratory monitoring is needed and adverse effects are minimal. Where oral therapy is genuinely needed, oral terbinafine can be dosed by weight under prescriber direction (broadly: 62.5 mg/day for 10-20 kg, 125 mg/day for 20-40 kg, and the adult 250 mg/day dose above 40 kg, each for 2 weeks); oral itraconazole and fluconazole can also be used off-label with weight-based dosing.^[1]

Diabetes and peripheral vascular disease

Treat actively rather than deferring to a routine self-care trial — these patients carry a materially higher risk of secondary bacterial infection, cellulitis, and, in diabetes specifically, limb-threatening complications arising from an infected foot.^[3] Favor a lower threshold for oral therapy, closer follow-up, and prompt escalation if any sign of secondary infection develops; podiatry involvement is reasonable for recurrent or hyperkeratotic disease in this group.

Immunosuppression

Presentation can be more extensive or atypical, and self-care alone is not appropriate as the sole management — involve a prescriber for diagnosis confirmation and consider oral therapy or combination oral-plus-topical treatment.

Monitoring & Follow-Up

Reassess at the end of the planned course — 1 week for topical terbinafine in interdigital disease, 4 weeks (or longer) for azoles, tolnaftate, or moccasin-type disease, and 2 weeks for oral terbinafine — rather than waiting for the patient to bring it up. Confirm symptom resolution, and where the diagnosis was uncertain or treatment was extended, consider repeat KOH microscopy to confirm mycological cure rather than relying on appearance alone, since clinical improvement can lag behind, or mask, incomplete eradication.^[1]

Symptom and skin response

Check at the end of the planned course. Persistent scaling or pruritus beyond the expected endpoint needs reassessment, not simply repeating the same agent.

Secondary bacterial infection

Watch for new pain, spreading redness, warmth, swelling, or drainage at any point during treatment — assess promptly rather than assuming it is the fungal infection worsening.

Adherence

Ask directly whether the full course was completed, not just whether symptoms improved — early discontinuation once itching resolves is the leading cause of apparent failure.

Hepatotoxicity (oral antifungals only)

Ask about fatigue, jaundice, nausea, dark urine, or pale stools at follow-up; obtain baseline and, where risk factors are present, on-treatment liver function tests.

Treatment Failure / Next Step

Confirm the diagnosis is actually tinea pedis — obtain KOH microscopy or fungal culture rather than assuming the same drug simply needs more time; contact dermatitis, psoriasis, and candidal intertrigo are common misdiagnoses that will not respond to an antifungal.
Confirm adherence to the full prescribed duration and correct application technique — a thin layer over the affected area and a margin of normal-appearing skin, not just the visibly scaling patch.
Confirm the nonpharmacologic measures — foot drying, sock/footwear hygiene, treating a concurrent nail or groin infection — were actually followed, since an untreated reservoir will reseed the skin regardless of which topical is used.
If diagnosis, adherence, and hygiene measures are all confirmed but the response is still inadequate, move from topical to oral therapy (or add topical to an existing oral regimen), and treat moccasin-type disease with an extended course rather than repeating a short one.
Persistent infection despite an adequate, adherent oral course warrants referral to dermatology — consider a resistant organism or a non-dermatophyte mould requiring a different antifungal class.

Common Errors to Avoid

Treating a symmetric, bilateral, sharply demarcated plaque as tinea pedis without first considering psoriasis or contact dermatitis.
Using tolnaftate when a candidal component is plausible — it has no anti-yeast activity.
Under-treating moccasin (hyperkeratotic) tinea pedis with a 1-week course intended for interdigital disease — this subtype needs a longer course, and often more.
Stopping treatment as soon as itching or visible scaling improves, before the full course is complete — the leading cause of apparent treatment failure and early recurrence.
Treating the skin but ignoring a concurrent fungal nail or groin infection that continues to reseed the foot.
Missing early cellulitis in a patient with diabetes or peripheral vascular disease by treating spreading erythema, warmth, or pain as "just fungal."
Prescribing oral itraconazole without screening for CYP3A4 drug interactions first.
Defaulting to oral griseofulvin or ketoconazole out of habit rather than using terbinafine, itraconazole, or fluconazole, which have better efficacy and/or safety profiles for this indication.^[1]
Not counselling on footwear and sock hygiene, leaving the environmental driver of recurrence unaddressed even after a technically successful antifungal course.

Clinical Decision Algorithm

Algorithm A — Confirm the presentation and triage

Suspected tinea pedis: scaling, maceration, vesicles, or erosions of the foot

Assess distribution/subtype and check for red flags: spreading erythema/warmth/pain, fever, diabetes, PVD, immunosuppression, or extensive/nail/groin involvement

Red flags present

Refer for medical assessment — treat as possible cellulitis/complicated infection, not routine self-care

Presentation atypical or diagnosis uncertain

Obtain KOH microscopy or fungal culture before treating; reconsider contact dermatitis, psoriasis, candidal intertrigo, or bacterial infection

Classic, uncomplicated interdigital, moccasin, or vesiculobullous pattern

Proceed to Algorithm B — subtype-directed self-care

Algorithm B — Subtype-directed topical self-care

Uncomplicated tinea pedis confirmed

Interdigital

Topical terbinafine 1% cream BID x 1 week (preferred); clotrimazole/miconazole BID x 4 weeks or tolnaftate BID x 2-4 weeks as alternatives

Moccasin (hyperkeratotic)

Topical antifungal BID for at least 4 weeks; add a salicylic acid keratolytic to improve penetration

Vesiculobullous

Topical antifungal per interdigital dosing; a remote hand "id" reaction may accompany it and resolves once the foot infection clears — no separate treatment needed

Reinforce foot-drying, sock/footwear hygiene, and completing the full course even after symptoms improve

Resolved at the expected endpoint

Mycological and clinical cure — continue hygiene measures to prevent recurrence

No improvement, or worsening, at the expected endpoint

Treatment failure — proceed to Algorithm C

Algorithm C — Treatment failure and escalation

Inadequate response to an appropriate topical course

Confirm diagnosis (KOH/culture), confirm adherence and technique, confirm hygiene measures and any concurrent nail/groin infection were addressed

Diagnosis, adherence, and hygiene measures all confirmed adequate

Move to oral therapy — terbinafine 250 mg daily x 2 weeks (1st line); itraconazole 200 mg BID x 1 week or fluconazole 150 mg weekly x 2-6 weeks as alternatives

A specific gap identified: misdiagnosis, nonadherence, untreated reservoir, or unaddressed hygiene factor

Correct the specific gap directly and retreat before escalating to oral therapy

Persistent infection despite an adequate, adherent oral course: refer to dermatology; consider a resistant organism or a non-dermatophyte mould

Drug Tables

How to use this table: Doses are adult doses unless a separate pediatric line is given, and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page.

Allylamines (topical and oral)

First-line class for most tinea pedis given the shortest effective topical course and, for oral use, the fewest clinically significant interactions.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Terbinafine, topical 1% cream	Interdigital: Apply BID for 1 week Moccasin (hyperkeratotic): Apply BID for up to 4 weeks or longer	Local irritation, burning, stinging, dryness	None clinically significant given minimal systemic absorption	1st-line topical agent for interdigital disease given its short course. Continue for the full duration even after itching resolves.
Terbinafine, oral	Adults: 250 mg PO once daily for 2 weeks Children 10 to under 20 kg: 62.5 mg PO once daily for 2 weeks Children 20-40 kg: 125 mg PO once daily for 2 weeks Children over 40 kg: 250 mg PO once daily for 2 weeks	GI upset, headache, transient taste/smell disturbance, rash; rare hepatotoxicity, blood dyscrasias	Terbinafine inhibits CYP2D6, raising levels of tricyclic antidepressants, SSRIs (fluoxetine, paroxetine), tramadol, atomoxetine, and beta-blockers metabolized via CYP2D6; cimetidine decreases and rifampin increases terbinafine clearance	1st-line oral agent for extensive, refractory, or moccasin-type disease, or when tinea pedis coexists with onychomycosis. Obtain baseline liver function tests if other hepatotoxicity risk factors are present.

Azoles (topical and oral)

Effective, widely available OTC topical options; a longer course than terbinafine is needed for cure.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Clotrimazole, topical 1% cream	Dosing: Apply BID for 4 weeks	Local irritation, burning, contact dermatitis (uncommon)	None clinically significant given minimal systemic absorption	OTC alternative to terbinafine; adherence over the full 4-week course is the main limiting factor for cure.
Miconazole, topical 2% cream/powder/spray	Dosing: Apply BID for 4 weeks	Local irritation, burning	None clinically significant given minimal systemic absorption	Comparable efficacy and dosing rationale to clotrimazole. Powder/spray forms are also used inside footwear for prevention.
Itraconazole, oral (pulse)	Adults: 200 mg PO BID for 1 week	GI upset, headache; rare hepatotoxicity, heart failure	Potent CYP3A4 inhibitor — avoid or use with caution with statins metabolized via CYP3A4 (atorvastatin/lovastatin/simvastatin), calcium channel blockers, digoxin, warfarin, and other CYP3A4 substrates; H2-antagonists and proton pump inhibitors reduce absorption	Alternative oral agent to terbinafine. Screen the full medication list for CYP3A4 interactions before dispensing.
Fluconazole, oral	Adults: 150 mg PO once weekly for 2-6 weeks	Nausea, headache; rare hepatotoxic reactions	Inhibits CYP2C9/CYP2C19/CYP3A4 — raises levels of warfarin, phenytoin, sulfonylureas, and several other substrates; monitor for toxicity	Further oral alternative when terbinafine and itraconazole are unsuitable; lower comparative efficacy than either.

Thiocarbamates (topical)

Nonprescription option; no activity against Candida.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Tolnaftate, topical 1% cream/solution/powder	Treatment: Apply BID for 2-4 weeks Prevention: Apply once daily to feet and inside footwear	Local irritation (uncommon)	None clinically significant given minimal systemic absorption	Fungistatic rather than fungicidal. Not effective against Candida — avoid if a yeast component is suspected. Powder form is also used preventively inside footwear.

Hydroxypyridones (topical)

Broader-spectrum option when secondary bacterial colonization accompanies the fungal infection.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Ciclopirox, topical 0.77% cream	Dosing: Apply BID for up to 4 weeks	Local irritation	None clinically significant given minimal systemic absorption	Combined antifungal, anticandidal, and antibacterial activity — a reasonable choice for the macerated, malodorous "dermatophytosis complex" presentation.

Keratolytic adjunct

Not an antifungal — used alongside topical or oral therapy to improve penetration through hyperkeratotic scale.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Salicylic acid	Dosing: Apply per product directions concurrently with the antifungal	Local irritation, stinging	None clinically significant with topical foot use	Adjunct for moccasin (hyperkeratotic) tinea pedis; softens thickened scale so the antifungal penetrates more effectively.

Oral agents generally not recommended for this indication

Listed to state explicitly that these should not be first choices for tinea pedis, not as routine options.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Griseofulvin, oral	Use in tinea pedis: Not a preferred agent — use terbinafine, itraconazole, or fluconazole first	Photosensitivity, GI upset, headache, hepatic dysfunction; contraindicated in pregnancy	Induces hepatic CYP enzymes — reduces efficacy of warfarin and hormonal contraceptives	Poor bioavailability and a longer required course than terbinafine, with a less favourable adverse-effect profile. Reserve for situations where the preferred oral agents cannot be used.
Ketoconazole, oral	Use in tinea pedis: Not recommended — do not use	Hepatotoxicity, adrenal suppression at higher exposure	Potent CYP3A4 inhibitor with an extensive interaction list	Largely abandoned for dermatophyte infections given hepatotoxicity and neurologic/endocrine risk relative to terbinafine, itraconazole, or fluconazole.

References

Tinea pedis: an updated review — Drugs in Context (Leung AKC, Barankin B, Lam JM, Leong KF, Hon KL). Drugs Context 2023;12:1-16
Topical management of tinea pedis — Canadian Family Physician, Tools for Practice (adapted from the Alberta College of Family Physicians' PEER evidence program) (Thomas B, Falk J, Allan GM). Can Fam Physician 2021;67(1):30
Fungal foot infection, cellulitis and diabetes: a review — Diabetic Medicine (Bristow IR, Spruce MC). Diabet Med 2009;26(5):548-551
Consensus for the treatment of tinea pedis: a systematic review of randomised controlled trials — Journal of Fungi (Ward H, Parkes N, Smith C, Kluzek S, Pearson R). J Fungi (Basel) 2022;8(4):351

Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.